Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab induction with rapid steroid withdrawal in blood-group compatible pediatric liver transplantation
ChiCTR1800019323Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of basiliximab in hepatic disease (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Recipient survival rate, Graft survival rate and 2 more. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
basiliximab
03
Conditions
hepatic disease
Beyond the preview
Go deeper on ChiCTR1800019323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019323.